{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:09:56Z","timestamp":1779912596148,"version":"3.53.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0207170","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T14:35:59Z","timestamp":1551796559000},"page":"e0207170","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib"],"prefix":"10.1371","volume":"14","author":[{"given":"Hiroaki","family":"Kitamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-0346","authenticated-orcid":true,"given":"Yoko","family":"Tabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Yuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Misawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Ohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","article-title":"Ever-advancing chronic myeloid leukemia treatment","volume":"19","author":"S Kimura","year":"2014","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"SG O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"24","key":"ref3","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"G Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"ref4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"H Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"28","key":"ref5","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"JE Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl_4","key":"ref6","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"A Hochhaus","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"J Cortes","year":"2007","journal-title":"Blood"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"M Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref9","article-title":"National Comprehensive Cancer Network\u2014Chronic Myloid Leukemia","author":"NCC Network","journal-title":"National Comprehensive Cancer Network\u2014Chronic Myloid Leukemia"},{"issue":"35","key":"ref10","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"M Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15","key":"ref11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"TP Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"NC Cross","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"ref13","first-page":"42","article-title":"Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management","volume":"7","author":"S Bauer","year":"2016","journal-title":"J Adv Pract Oncol"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"F Rossari","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"J Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"D Rea","year":"2017","journal-title":"Blood"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12892","article-title":"How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia","volume":"166","author":"DM Ross","year":"2014","journal-title":"Br J Haematol"},{"key":"ref19","article-title":"Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study","author":"N Takahashi","year":"2017","journal-title":"Int J Hematol"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"NC Cross","year":"2015","journal-title":"Leukemia"},{"issue":"22","key":"ref21","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","article-title":"Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA","volume":"116","author":"HE White","year":"2010","journal-title":"Blood"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1373\/clinchem.2012.196477","article-title":"Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale","volume":"59","author":"HE White","year":"2013","journal-title":"Clin Chem"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/ijlh.12274","article-title":"Harmonization of quantitative BCR-ABL measurements using the secondary reference material anchored to the WHO primary standards","volume":"37","author":"H Yamada","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"ref24","article-title":"Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)","author":"S Fujisawa","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","article-title":"Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan","volume":"17","author":"C Yoshida","year":"2012","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12185-015-1826-9","article-title":"A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits","volume":"102","author":"H Nakamae","year":"2015","journal-title":"Int J Hematol"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.5858\/arpa.2016-0504-CP","article-title":"Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology","volume":"141","author":"DA Arber","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"13\u201314","key":"ref28","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.clinbiochem.2014.05.067","article-title":"Calibration of BCR-ABL1 mRNA quantification methods using genetic reference materials is a valid strategy to report results on the international scale","volume":"47","author":"C Maute","year":"2014","journal-title":"Clin Biochem"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10428194.2016.1190974","article-title":"Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices","volume":"58","author":"R Arora","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1186\/s40064-016-2258-6","article-title":"Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale","volume":"5","author":"C Yoshida","year":"2016","journal-title":"Springerplus"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11864-018-0532-2","article-title":"When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia","volume":"19","author":"P. Laneuville","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjh.14557","article-title":"Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme","volume":"177","author":"S Scott","year":"2017","journal-title":"Br J Haematol"},{"key":"ref33","article-title":"Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib","author":"FE Nicolini","year":"2018","journal-title":"Exp Hematol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0207170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T03:21:04Z","timestamp":1588994464000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0207170"}},"subtitle":[],"editor":[{"given":"Xiaoyan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0207170","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/455956","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]}}}